ArticleJournal of veterinary internal medicine2026
Survival of dogs with glomerular disease in Europe: insights from the European Veterinary Renal Pathology Service.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough glomerular disorders contribute to chronic kidney disease in dogs, few studies have evaluated the usefulness of renal biopsy for predicting outcome. HYPOTHESIS/
objectivesInvestigate morphologic diagnoses, clinicopathological findings, comorbidities, treatment, and their associations with survival in dogs after renal biopsy. ANIMALS: One hundred ten client-owned dogs with glomerular disease.
methodsRetrospective cohort study of medical records from the European Veterinary Renal Pathology Service (2018-2023). Data were obtained before referral for renal biopsy and during follow-up. Survival analysis was performed using the Kaplan-Meier method, followed by log-rank tests. Relative risk was calculated using contingency tables.
resultsDogs were classified into 3 groups: immune complex glomerulonephritis (ICGN) (61 dogs, 56%), non-ICGN (39 dogs, 35%), and juvenile nephropathy (JN) (10 dogs, 9%). Survival was longer in ICGN dogs than non-ICGN (mean ± SEM: 951 ± 78 days vs. 613 ± 92 days; P = .02), with no difference versus JN (1004 ± 169). No survival differences were observed among the morphological subtypes of ICGN. Dogs with amyloidosis had shorter survival than all other morphologic non-ICGN subtypes (384 ± 95 vs. 650 ± 56 days, P = .02). Risk of a creatinine increase of ≥50% during follow-up was greater in the JN group (RR = 2.78; 95% CI, 1.60-4.84; P = .03). Reduction in proteinuria ≥50% during follow-up did not differ between groups. Immunosuppressive treatment was more frequently administered to ICGN dogs (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Immune complex glomerulonephritis dogs had better outcomes and slower disease progression than non-ICGN and JN. Proteinuria decreased by approximately 50% within each group over time; however, the retrospective design precludes conclusions regarding the effect of antiproteinuric treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.